Mild cognitive impairment

A concept in evolution

Ronald Carl Petersen, B. Caracciolo, C. Brayne, S. Gauthier, V. Jelic, L. Fratiglioni

Research output: Contribution to journalArticle

377 Citations (Scopus)

Abstract

The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive ageing and MCI need to be performed to clarify all these issues.

Original languageEnglish (US)
Pages (from-to)214-228
Number of pages15
JournalJournal of Internal Medicine
Volume275
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Biomarkers
Population
Patient Selection
Longitudinal Studies
Dementia
Publications
Cognitive Dysfunction
Phenotype
Research
Datasets
Cognitive Aging

Keywords

  • Alzheimer's disease
  • Dementia
  • Memory impairment
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014). Mild cognitive impairment: A concept in evolution. Journal of Internal Medicine, 275(3), 214-228. https://doi.org/10.1111/joim.12190

Mild cognitive impairment : A concept in evolution. / Petersen, Ronald Carl; Caracciolo, B.; Brayne, C.; Gauthier, S.; Jelic, V.; Fratiglioni, L.

In: Journal of Internal Medicine, Vol. 275, No. 3, 2014, p. 214-228.

Research output: Contribution to journalArticle

Petersen, RC, Caracciolo, B, Brayne, C, Gauthier, S, Jelic, V & Fratiglioni, L 2014, 'Mild cognitive impairment: A concept in evolution', Journal of Internal Medicine, vol. 275, no. 3, pp. 214-228. https://doi.org/10.1111/joim.12190
Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: A concept in evolution. Journal of Internal Medicine. 2014;275(3):214-228. https://doi.org/10.1111/joim.12190
Petersen, Ronald Carl ; Caracciolo, B. ; Brayne, C. ; Gauthier, S. ; Jelic, V. ; Fratiglioni, L. / Mild cognitive impairment : A concept in evolution. In: Journal of Internal Medicine. 2014 ; Vol. 275, No. 3. pp. 214-228.
@article{9b705951c3694aceb5517a52188e1909,
title = "Mild cognitive impairment: A concept in evolution",
abstract = "The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive ageing and MCI need to be performed to clarify all these issues.",
keywords = "Alzheimer's disease, Dementia, Memory impairment, Mild cognitive impairment",
author = "Petersen, {Ronald Carl} and B. Caracciolo and C. Brayne and S. Gauthier and V. Jelic and L. Fratiglioni",
year = "2014",
doi = "10.1111/joim.12190",
language = "English (US)",
volume = "275",
pages = "214--228",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Mild cognitive impairment

T2 - A concept in evolution

AU - Petersen, Ronald Carl

AU - Caracciolo, B.

AU - Brayne, C.

AU - Gauthier, S.

AU - Jelic, V.

AU - Fratiglioni, L.

PY - 2014

Y1 - 2014

N2 - The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive ageing and MCI need to be performed to clarify all these issues.

AB - The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive ageing and MCI need to be performed to clarify all these issues.

KW - Alzheimer's disease

KW - Dementia

KW - Memory impairment

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84895749376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895749376&partnerID=8YFLogxK

U2 - 10.1111/joim.12190

DO - 10.1111/joim.12190

M3 - Article

VL - 275

SP - 214

EP - 228

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 3

ER -